We are live on
!
Find out more
CC
Caxton Corporation Portfolio holdings
AUM
$4.02M
1-Year Est. Return
256.08%
This Fund
S&P 500
This Quarter
Est. Return
+20.72%
1 Year Est. Return
+256.08%
3 Year Est. Return
+777.99%
5 Year Est. Return
+744.68%
10 Year Est. Return
+18,621.85%
AUM
$18.5M
AUM Growth
-$7.8M
(-30%)
Cap. Flow
-$10.4M
Cap. Flow
% of AUM
-55.99%
Top 10 Holdings %
Top 10 Hldgs %
99.27%
Holding
14
New
5
Increased
–
Reduced
4
Closed
2
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$589K |
| 2 |
Berkshire Hathaway Class B
BRK.B
|
+$363K |
| 3 |
ABVX
Abivax
ABVX
|
+$171K |
| 4 |
Lexeo Therapeutics
LXEO
|
+$128K |
| 5 |
HARP
Harpoon Therapeutics, Inc. Common Stock
HARP
|
+$104K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Savara
SVRA
|
+$11.3M |
| 2 |
Aclaris Therapeutics
ACRS
|
+$133K |
| 3 |
Apogee Therapeutics
APGE
|
+$103K |
| 4 |
Compass Therapeutics
CMPX
|
+$74.9K |
| 5 |
ALLK
Allakos
ALLK
|
+$55.5K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 94.62% |
| 2 | Financials | 1.99% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
Xeris Biopharma Holdings
XERS
$1.52B
| $13.3M | 71.57% |
5,641,920
| – | – |
|
|
2
Savara
SVRA
$1.13B
| $1.66M | 8.97% |
353,441
-2,960,161
| -89% | -$11.3M |
|
3
Rezolute
RZLT
$444M
| $1.31M | 7.07% |
1,318,967
| – | – |
|
|
4
State Street SPDR S&P 500 ETF Trust
SPY
$774B
| $628K | 3.39% |
+1,322
| New | +$589K |
|
|
MTEM
5
DELISTED
Molecular Templates, Inc.
MTEM
| $511K | 2.76% |
136,866
| – | – |
|
|
6
Berkshire Hathaway Class B
BRK.B
$1.06T
| $369K | 1.99% |
+1,035
| New | +$363K |
|
|
7
Apogee Therapeutics
APGE
$10.1B
| $205K | 1.11% |
7,353
-5,119
| -41% | -$103K |
|
|
ABVX
8
Abivax
ABVX
$11.9B
| $179K | 0.97% |
+16,743
| New | +$171K |
|
|
9
Lexeo Therapeutics
LXEO
$368M
| $138K | 0.75% |
+10,319
| New | +$128K |
|
|
HARP
10
DELISTED
Harpoon Therapeutics, Inc. Common Stock
HARP
| $129K | 0.7% |
+13,176
| New | +$104K |
|
|
11
Compass Therapeutics
CMPX
$369M
| $67.8K | 0.37% |
43,465
-43,308
| -50% | -$74.9K |
|
|
ALLK
12
DELISTED
Allakos
ALLK
| $67.5K | 0.36% |
24,710
-24,619
| -50% | -$55.5K |
|
|
13
Aclaris Therapeutics
ACRS
$793M
| – | – |
-19,473
| Closed | -$133K |
|
|
ELEV
14
DELISTED
Elevation Oncology
ELEV
| – | – |
-21,813
| Closed | -$14.5K |
|
Similar funds
PCM
EAMS
RCP
RA
CGA
HFA
ABA
UOMF
Caxton Corporation's Q4 2023 Portfolio in Review
As of Q4 2023, Caxton Corporation held 14 positions worth $18.5M, down 30% from $26.3M the previous quarter. Its ten largest holdings account for 99% of the portfolio.
Caxton Corporation withdrew a net $10.4M in Q4 2023, closing 2 positions and reducing 4 holdings. Its most notable exit was Aclaris Therapeutics, an estimated $133K position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 95% of assets, down from 100% a quarter earlier, followed by Financials.
Against the trend, Caxton Corporation opened a new position in State Street SPDR S&P 500 ETF Trust worth $628K.
- Caxton Corporation's largest Q4 2023 buy was State Street SPDR S&P 500 ETF Trust: 1,322 shares worth $628K.
- Caxton Corporation's biggest Q4 2023 reduction was Savara, cutting an estimated $11.3M.
- Caxton Corporation fully exited Aclaris Therapeutics in Q4 2023, selling an estimated $133K.
- Caxton Corporation's ten largest holdings make up 99% of its $18.5M portfolio in Q4 2023.
- Caxton Corporation opened 5 new positions and closed 2 in Q4 2023.
- Caxton Corporation's portfolio value fell 30% quarter-over-quarter to $18.5M.
Based on Caxton Corporation's 13F filing for Q4 2023, filed 14 Feb 2024.